| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Financial Officer | CFO
2 companies
Terry-Ann Burrell last filed a Form 4 in July 2024, as Chief Financial Officer at BEAM. The filings on record cover 2 companies. Terry-Ann Burrell's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Terry-Ann Burrell's trades have earned a strong insider score of 81/100 across 13 rated trades. Over a 12-month horizon, 84.6% of those trades were profitable, with an average 12-month return of +39.9%.
At the last filing, the largest reported position was 82,637 shares of BEAM. The BEAM filings lean toward selling, a net 216,558 shares.
Terry-Ann Burrell has 31 Form 4 filings on record from September 2020 to July 2024, across 2 companies: Director at Recursion Pharmaceuticals (RXRX), 2021–2024; Chief Financial Officer at Beam Therapeutics (BEAM), 2020–2024.
The 70 reported transactions were 30 open-market sales, 18 stock awards, 9 option or other derivative awards and 9 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 10 sales worth about $17.1M.
The largest open-market sale was 45,000 shares of BEAM at an average $107.69 on June 28, 2021, about $4.8M. Twelve months later BEAM was down 63%.
2 of the 3 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other was not.
Shares as reported in the last Form 4 for each company; the most recent is from July 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1, 2024 | BEAM Beam Therapeutics Inc. | Chief Financial Officer | Sell10b5-1 | 5,446 | $32.12 | $174,925.52 | -7.2% | -29.4% | -46.0% | |
| Jul 13, 2023 | RXRX Recursion Pharmaceuticals, Inc. | Director | Sell | 117,000 | $12.07 | $1,412,413.53 | -68.1% | -45.2% | -32.8% | |
| Apr 4, 2023 | BEAM Beam Therapeutics Inc. | Chief Financial Officer | Sell10b5-1 | 4,640 | $29.74 | $137,978.26 | -9.0% | +8.0% | +0.4% | |
| Jan 27, 2023 | BEAM Beam Therapeutics Inc. | Chief Financial Officer | Sale+OE | 37,254 | $45.08 | $1,679,509.86 | -54.4% | -32.7% | -46.4% | |
| Jan 24, 2023 | BEAM Beam Therapeutics Inc. | Chief Financial Officer | Sale+OE | 20,236 | $45.02 | $910,947.25 | -39.3% | -31.5% | -44.4% | |
| Jan 18, 2023 | BEAM Beam Therapeutics Inc. | Chief Financial Officer | Sale+OE | 47,195 | $45.14 | $2,130,382.30 | -60.1% | -30.1% | -47.3% | |
| Mar 31, 2022 | BEAM Beam Therapeutics Inc. | CFO | Sell | 1,787 | $59.11 | $105,629.57 | -4.5% | -29.5% | -46.6% | |
| Jun 30, 2021 | BEAM Beam Therapeutics Inc. | CFO | Sale+OE | 30,000 | $122.00 | $3,660,000.00 | -54.7% | -29.2% | -69.9% | |
| Jun 28, 2021 | BEAM Beam Therapeutics Inc. | CFO | Sale+OE | 45,000 | $107.69 | $4,846,016.46 | -64.5% | -12.9% | -62.9% | |
| Jan 4, 2021 | BEAM Beam Therapeutics Inc. | CFO | Sale+OE | 25,000 | $81.78 | $2,044,484.79 | -77.4% | - | - |